Literature DB >> 10889399

Detection of fiducial gold markers for automatic on-line megavoltage position verification using a marker extraction kernel (MEK).

A Nederveen1, J Lagendijk, P Hofman.   

Abstract

PURPOSE: In this study automatic detection of implanted gold markers in megavoltage portal images for on-line position verification was investigated. METHODS AND MATERIALS: A detection method for fiducial gold markers, consisting of a marker extraction kernel (MEK), was developed. The detection success rate was determined for different markers using this MEK. The localization accuracy was investigated by measuring distances between markers, which were fixed on a perspex template. In order to generate images comparable to images of patients with implanted markers, this template was placed on the skin of patients before the start of the treatment. Portal images were taken of lateral prostate fields at 18 MV within 1-2 monitor units (MU).
RESULTS: The detection success rates for markers of 5 mm length and 1.2 and 1.4 mm diameter were 0.95 and 0.99 respectively when placed at the beam entry and 0.39 and 0.86 when placed at the beam exit. The localization accuracy appears to be better than 0.6 mm for all markers.
CONCLUSION: Automatic marker detection with an acceptable accuracy at the start of a radiotherapy fraction is feasible. Further minimization of marker diameters may be achieved with the help of an a-Si flat panel imager and may increase the clinical acceptance of this technique.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10889399     DOI: 10.1016/s0360-3016(00)00523-x

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  8 in total

1.  Prostate intrafraction motion evaluation using kV fluoroscopy during treatment delivery: a feasibility and accuracy study.

Authors:  Justus Adamson; Qiuwen Wu
Journal:  Med Phys       Date:  2008-05       Impact factor: 4.071

2.  Fast internal marker tracking algorithm for onboard MV and kV imaging systems.

Authors:  W Mao; R D Wiersma; L Xing
Journal:  Med Phys       Date:  2008-05       Impact factor: 4.071

3.  A novel approach for establishing benchmark CBCT/CT deformable image registrations in prostate cancer radiotherapy.

Authors:  Jinkoo Kim; Sanath Kumar; Chang Liu; Hualiang Zhong; Deepak Pradhan; Mira Shah; Richard Cattaneo; Raphael Yechieli; Jared R Robbins; Mohamed A Elshaikh; Indrin J Chetty
Journal:  Phys Med Biol       Date:  2013-10-31       Impact factor: 3.609

4.  Effect of magnesium oxide on interfraction prostate motion and rectal filling in prostate cancer radiotherapy: analysis of a randomized clinical trial.

Authors:  Annemarie M den Harder; Carla H van Gils; Alexis N T J Kotte; Marco van Vulpen; Irene M Lips
Journal:  Strahlenther Onkol       Date:  2014-04-24       Impact factor: 3.621

5.  Analysis of fiducial markers used for on-line verification in the external-beam radiotherapy of patients with cranial tumours.

Authors:  R Ma Cañón; I Azinovic; M Lobato; J Navarro; J Rebollo
Journal:  Clin Transl Oncol       Date:  2007-08       Impact factor: 3.405

6.  A dosimetric selectivity intercomparison of HDR brachytherapy, IMRT and helical tomotherapy in prostate cancer radiotherapy.

Authors:  Johanne Hermesse; Sylvie Biver; Nicolas Jansen; Eric Lenaerts; Nathalie De Patoul; Stefaan Vynckier; Philippe Coucke; Pierre Scalliet; Philippe Nickers
Journal:  Strahlenther Onkol       Date:  2009-11-10       Impact factor: 3.621

7.  A fiducial detection algorithm for real-time image guided IMRT based on simultaneous MV and kV imaging.

Authors:  Weihua Mao; Nadeem Riaz; Louis Lee; Rodney Wiersma; Lei Xing
Journal:  Med Phys       Date:  2008-08       Impact factor: 4.071

8.  Intrafractional prostate motion during external beam radiotherapy monitored by a real-time target localization system.

Authors:  Xu Tong; Xiaoming Chen; Jinsheng Li; Qianqian Xu; Mu-Han Lin; Lili Chen; Robert A Price; Chang-Ming Ma
Journal:  J Appl Clin Med Phys       Date:  2015-03-08       Impact factor: 2.102

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.